Based on this, we propose that inhibiting ASNS would be a much more specific way to reduce glutamine usage in polycystic kidney disease, opening an important opportunity for a more targeted approach in ADPKD treatment. This evidence concerns the gene ASNS and autosomal dominant polycystic kidney disease.